Elutia (NASDAQ:ELUT – Get Free Report) last posted its quarterly earnings data on Monday, August 14th. The company reported ($0.65) EPS for the quarter. The firm had revenue of $10.30 million for the quarter. On average, analysts expect Elutia to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Elutia Price Performance
NASDAQ ELUT opened at $1.47 on Friday. Elutia has a one year low of $1.10 and a one year high of $8.84. The company has a market capitalization of $23.89 million, a PE ratio of -0.65 and a beta of -0.02.
Analyst Ratings Changes
Institutional Trading of Elutia
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ELUT. Geode Capital Management LLC raised its holdings in Elutia by 32.2% during the fourth quarter. Geode Capital Management LLC now owns 14,112 shares of the company’s stock worth $59,000 after purchasing an additional 3,435 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Elutia in the 4th quarter valued at $1,062,000. Renaissance Technologies LLC acquired a new position in shares of Elutia in the 1st quarter valued at $33,000. Finally, Jane Street Group LLC acquired a new position in shares of Elutia in the 1st quarter valued at $29,000. Institutional investors and hedge funds own 18.50% of the company’s stock.
Elutia Inc, a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. It offers CanGaroo Envelope, which is used for the stabilization of implantable cardiac devices, such as pacemakers and defibrillators. The company also engages in the development of CanGaroo RM for delivery directly to the surgical site.
- Five stocks we like better than Elutia
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Data giants MongoDB and Snowflake just got upgraded
- Best Aerospace Stocks Investing
- Plug Power at tipping point; it’s make or break time for hydrogen
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Palantir’s Q3 earnings beat: Time to buy despite analyst caution?
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.